Acquisition Opportunity Following the acquisition by VION Biosciences, there may be cross-sell opportunities for enzymatic assay kits, HTS reagents, and assay design and development services to the new parent company and its customers.

HTS Enablement Solutions The company offers high-throughput assay kits and reagents, along with assay customization and lead discovery services, making it a good partner for CROs and biotech R&D teams seeking ready-to-use HTS workflows.

Non-Radioactive Focus Emphasis on safe, non-radioactive detection methods (absorbance, fluorescence, luminescence) with simple workflows and minimal optimization, translating into broad appeal for labs prioritizing quick adoption and regulatory simplicity.

Instrumentation & Services Portfolio spans equipment (cell analyzers, handheld readers, microplate readers) and supportive services (analytical services, assay development, lead discovery), enabling end-to-end solutions from tools to custom assays.

Growth and Partnerships With revenue in the 10-25 million range and a lean team, there is room to pursue distribution partnerships, OEM arrangements, or strategic collaborations with larger life sciences players to scale sales and geographic reach.